MOB

Moberg Pharma

Research interview

Print

Moberg Pharma: Videointervju med vd Peter Wolpert

to view this content. Not a member?
Why should I sign up?
We’ll help you find the best stocks. With an account you gain access to all the research and information needed to improve your stock performance.
No commitment required
A few perks of having an account:
Full access to our research
Full access to our livestreams and video content
Customized research feed based on your preferences
Questions:
If you have any other questions, don’t hesitate to contact us at info@redeye.se or +46 (0)8 545 013 30

I en videointervju med Redeyes analytiker Klas Palin sammanfattar Peter Wolpert, vd på Moberg Pharma, det andra kvartalet som ett av det starkaste någonsin med tillväxt på 27 % och fördubblad lönsamhet.